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Abstract
Approximately up to 40% of patients with lung cancer develop bone metastasis, with 22% to 59% of them experi-
encing skeletal-related events (SREs), which result in an important quality of life deterioration and economic burden.
Denosumab, a fully human antibody that targets the receptor activator of nuclear factor-kB (RANK) ligand (RANKL), is
indicated for prevention of SREs in patients with solid tumors and has demonstrated superiority in breast and prostate
cancer, and in other solid tumors, in reducing the risk of ﬁrst SRE by 17% versus zoledronic acid. In the subset of
patients with nonesmall-cell lung carcinoma (NSCLC), denosumab has also shown a positive trend to SRE risk
reduction. Denosumab might have direct or indirect antitumor effects. Cancer cells produce factors that stimulate
increased bone resorption by osteoclasts, which in turn release tumor growth factors into the bone microenvironment,
initiating a tumor/bone vicious cycle. An increasing body of evidence suggests RANK/RANKL signaling plays a role in
this tumorigenesis. Both proteins are overexpressed in different tumor types including lung cancer cells. RANK/
RANKL signaling activates nuclear factor-kB pathways related to lung carcinogenesis and increases intercellular
adhesion molecule 1 expression and MEK/extracellular signal-regulated kinase phosphorylation, which in turn en-
hances tumor cell migration. In animal NSCLC models, denosumab delayed bone metastases and reduced skeletal
tumor growth. In patients with lung cancer (post hoc analysis), denosumab prolonged overall survival by 1.2 months
versus zoledronic acid (P ¼ .01). This hypothesis-generating outcome warrants further investigation and 2 studies in
lung cancer are ongoing to elucidate the therapeutic potential of denosumab beyond SRE prevention.
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Lung cancer is one of the most frequent cancers, and accounts for
approximately 20% of cancer mortality.1 Nonesmall-cell lung
cancer (NSCLC) is the most frequent type of lung cancer (85%).21Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
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http://dx.doi.org/10.1016/j.cllc.2015.06.004Currently, 1- and 5-year survival rates remain at approximately
45% and 12% of patients, respectively.3,4 In Europe, the incidence
and 5-year prevalence of lung cancer in 2012 were 410,220 and
442,810 individuals, respectively,1 of whom 71% were male.
Overall, the annual age-standardized mortality rate was 24.0 per
100,000.1 In Spain, the incidence and 5-year prevalence were
26,711 and 28,148 individuals, respectively.1 The 3-year survival
rate is approximately 13%.5
Because of the unspeciﬁc symptomatology of early disease, most
cases of NSCLC are diagnosed at an advanced stage (78%),6 with
bone being one of the most frequent sites of metastasis. The inci-
dence of bone metastases in the course of the disease ranges between
30% and 40%,7,8 and approximately 65% of cases are found at
diagnosis. The presence of bone metastases is related to a reduced
survival (median overall survival of 6-12 months7,9): multiple bone
lesions, high bone turnover marker levels, and history of patho-
logical fractures are also associated with a shorter survival.10Clinical Lung Cancer November 2015 - 431
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432 -Bone metastases in lung cancer are characterized mainly by severe
pain and lytic nature.11,12 Many asymptomatic bone lesions are not
diagnosed in clinical practice.8 Positron emission tomography
(PET) scans are the most common method of diagnosis,13 and have
a greater sensitivity than computed tomography (CT) scans.14 If
PET is not available, bone scintigraphy might be also useful. Cur-
rent guidelines recommend performing a CT scan of the chest and
upper abdomen at diagnosis of NSCLC for tumor staging.15 If bone
metastases are clinically suspected, bone imaging is required. In
addition to PET and CT for systemic screening, magnetic resonance
imaging is recommended to describe a localized bone metastasis. For
distant metastasis assessment, ﬂuorodeoxyglucoseePET-CT scan
offers the highest sensitivity.15
As a consequence of an impaired bone turnover, an important
proportion of patients with bone metastases experience
skeletal-related events (SREs).16-18 SREs are deﬁned as the
presence of pathologic fracture, radiation to bone, spinal cord
compression, or surgery to bone, and are a serious complication.
In a 21-month study, the incidence of SREs in lung cancer
patients with bone metastases who did not receive bone-targeted
agents ranged from 40% in patients without a history of SREs
(median of 209 days to ﬁrst SRE) to 52% in patients with pre-
vious SREs (median of 106 days).16 Another study in a large US
population reported that SREs were present in 22% of lung
cancer patients at diagnosis of bone metastasis, with a cumulative
incidence of 59%.19
Because of the need for surgery and lengthy hospitalizations
in most cases,20 these events have devastating consequences for
the quality of life of late-stage cancer patients.21 Most skeletal
complications also cause a decrease in the ability to perform
the basic functions of daily living, and have an effect on
mortality.22-24
The costs of managing patients with bone metastasis from lung
cancer who suffer SREs are much higher than those without a
SRE.25 In the United States, the estimated lifetime SRE-related cost
per lung cancer patient is $11,979, being mainly explained (61%)
by radiotherapy cost.26 In a European study in lung cancer patients
with at least 1 SRE, 41% of the events required hospitalization
during a median of 19 days.27 In several studies from Germany,28
Spain,28,29 Italy,28 the United Kingdom,28 Portugal,30 and
Belgium,31 costs of each SRE were in the following ranges: patho-
logic fractures: V4712 to V8730; radiation to bone, V1485 to
V3877; spinal cord compression: V7903 to V13,203; and surgery
to bone: V3348 to V12,092. In a French study of 554 lung cancer
patients with bone metastasis, 49.5% of yearly costs related to bone
metastasis could be assigned to SREs.32
Antiresorptive drugs, including denosumab and bisphosphonates,
are recommended for prevention of SREs in patients with lung
cancer and bone metastasis.33-35
Because bone metastases represent an important problem for the
patient and health system, their prevention and treatment are key in
the management of lung cancer. Denosumab is a bone-targeted
agent for treatment of metastatic bone disease. Herein, we review
the available evidence on its efﬁcacy in preventing skeletal compli-
cations in lung cancer patients with bone metastasis, and also the
increasing body of evidence that supports a potential direct anti-
tumor effect of denosumab.Clinical Lung Cancer November 2015Current Management of Bone
Metastasis in Lung Cancer
Zoledronic acid, the most effective bisphosphonate, has been
historically considered the standard of care for the prevention of
skeletal complications in patients with bone metastasis from lung
cancer. In a phase III study (n ¼ 773), zoledronic acid signiﬁcantly
delayed the median time to ﬁrst SRE (236 vs. 155 days; P ¼ .009)
and reduced the risk of a SRE by 31% versus placebo (hazard ratio
[HR], 0.69; 95% conﬁdence interval [CI], 0.54-0.88; P ¼ .003,
multiple event analysis).18 Although the trial was only powered for
the primary end point, a subset analysis in the NSCLC subgroup
found a trend toward a longer time to ﬁrst SRE (median 171 vs. 151
days; P ¼ .188) and a 27% reduction in the risk of SREs in favor of
4 mg zoledronic acid (HR, 0.73; 95% CI, 0.52-1.02; P ¼ .061)
versus the placebo group.36 An important limitation for zoledronic
acid use is the potential nephrotoxicity, which could be increased by
the comorbidities commonly associated with lung cancer, older age
and tobacco use, and by the platinum-based chemotherapy.
Cisplatin-based regimens are a common treatment option in pa-
tients with bone metastases, and are associated with dose-dependent
nephrotoxicity.37 Zoledronic acid therapy must be accompanied by
renal monitoring and requires dose adjustments in patients with
renal insufﬁciency, which might lead to suboptimal efﬁcacy.38 In
lung cancer, up to 23% of patients have creatinine clearance
(CrCl) < 60 mL/min.39 Zoledronic acid is contraindicated in pa-
tients with CrCl < 30 mL/min, and must be reduced from 4.0 to
3.5 mg in patients with a CrCl between 60 and 50 mL/min, to 3.3
mg in those with a CrCl between 50 and 40 mL/min, and to 3.0 mg
in those whose CrCl is within 40 to 30 mL/min.40 Renal adverse
effects lead to withdrawals in many cases (17% and 9%, respec-
tively41). Globally, only between 15%42 and 34%43 of patients with
bone metastases from lung cancer receive intravenous (I.V.)
bisphosphonates in the United States, and only 1 in 10 receive them
in a preventive way (ie, before a SRE) (5% vs. 10% for primary vs.
secondary prophylaxis).42
Denosumab in the Prevention of
Skeletal Complications
Denosumab is a fully human monoclonal antibody (immuno-
globulin [Ig] G2) that targets and binds with high afﬁnity
and speciﬁcity to the receptor activator of nuclear factor-kB
(RANK) ligand (RANKL), mimicking the natural action of osteo-
protegerin (OPG), an endogenous RANKL inhibitor.44 RANK is a
member of the tumor necrosis factor (TNF) receptor superfamily.45
Activation of RANK by the RANKL promotes the maturation of
preosteoclasts into osteoclasts.46 In metastatic bone disease, tumor
cells secrete factors that increase the expression of RANKL, upre-
gulating osteoclast activity which, in turn, releases growth factors
from the bone matrix that might perpetuate tumor activity.47,48
Denosumab prevents the RANK/RANKL interaction from occur-
ring, which inhibits the formation, function, and survival of acti-
vated osteoclasts and blocks the vicious cycle of bone destruction
and tumor growth (Figure 1).46-48
Denosumab has been approved globally for prevention of SREs
in patients with solid tumors.44,49 The recommended dose for
prevention of SREs in adults with bone metastasis from solid tu-
mors is 120 mg administered as a single subcutaneous injection
Javier De Castro et alonce every 4 weeks into the thigh, abdomen, or upper arm.44
Denosumab does not need dose adjustment according to renal
function, or renal monitoring.44
Phase III Studies in Cancer Patients With Bone
Metastasis
The effects of denosumab on skeletal complications in patients
with bone metastasis have been evaluated in 3 large phase III studies
versus zoledronic acid: 1 in breast cancer,50 1 in prostate cancer,51
and the other in solid tumors and multiple myeloma.41 All studies
were of identical design, which allowed for a preplanned integrated
analysis of data to be performed.52 The primary end point was time
to ﬁrst SRE during the study, which was assessment for treatment
noninferiority. If noninferiority was proven, treatment superiority
was tested as a secondary end point.
In patients with breast and prostate cancer, denosumab was
superior to zoledronic acid in delaying time to ﬁrst SRE during the
study, and was associated with a greater reduction in bone turnover
markers.50,51 No differences were observed between the 2 treat-
ment arms in terms of overall survival, progression-free survival,
and adverse events (AEs), including osteonecrosis of the jaw. When
the 3 studies (breast, prostate, and other solid tumor and multiple
myeloma) were combined, the median time to ﬁrst SRE was
delayed by 8.2 months in patients who received denosumab versus
zoledronic acid (HR, 0.83; 95% CI, 0.76-0.90; P < .0001 supe-
riority), with a reduction of 17% in the risk of a ﬁrst SRE.52
Subgroup analyses showed a consistent effect of denosumab in
patients with and without previous SREs. The reduction in the risk
of a ﬁrst SRE was 16% in patients with previous SREs (HR, 0.84;
95% CI, 0.73-0.96; P ¼ .01), and 18% in patients who had
not experienced a previous SRE (HR, 0.82; 95% CI, 0.73-0.92;
P ¼ .0006).52 Other subgroup analyses also showed a consistent
effect in patients older and younger than 65 years,52 and in several
subsets according to different baseline characteristics: location of
skeletal metastases (axial vs. appendicular), presence of visceral
metastases (yes/no), urinary N-telopeptide level (median;  43.5
vs. < 43.5 nmol/mmol), number of bone metastases (< 2 or  2),Figure 1 Mechanism of Action of Denosumab in Cancer Patientsand Eastern Cooperative Oncology Group (ECOG) performance
status (0 or  1).53
Efﬁcacy and Safety in Lung Cancer
Data regarding the use of denosumab in patients with lung cancer
and bone metastasis are available from the pivotal phase III study in
1776 patients with bone metastasis from advanced cancer
(excluding breast and prostate cancers) or multiple myeloma.41
Among the 1776 patients, 1597 patients had solid tumors, 811 of
whom had lung cancer (702 NSCLC). Primary efﬁcacy results for
the SRE end points in the overall study population and in the
subsets of patients with solid tumors and with NSCLC are sum-
marized in Table 1.41,54 In the overall population, denosumab was
noninferior, but not statistically superior, to zoledronic acid in
delaying time to ﬁrst SRE during the study or time to ﬁrst and
subsequent SREs (rate ratio, 0.90; 95% CI, 0.77-1.04; P ¼ .14). In
the subset of patients with solid tumors, denosumab was superior to
zoledronic acid.54 Although the trial was only powered for the
primary end point (in the overall population), in the subset of pa-
tients with NSCLC denosumab also showed a trend to a delayed
time to ﬁrst SRE during the study relative to zoledronic acid (HR,
0.85; 95% CI, 0.65-1.12; P ¼ .25).41
Safety results for the overall study population are summarized in
Table 2. In patients with lung cancer, AEs were reported in 96.8%
and 95.4% of patients in the denosumab (n ¼ 406) and zoledronic
acid (n ¼ 395) arms, respectively, and included hypocalcemia
(8.6% vs. 3.8%, respectively) and osteonecrosis of the jaw (0.7% vs.
0.8%, respectively).41 The lower frequency of AEs in the subgroup
of lung cancer patients can be explained by the shorter survival time
in this population.
Cost-Effectiveness in Lung Cancer
Most pharmacoeconomic evaluations published between 2011
and 2013 in lung cancer patients or in solid tumor patients
(including lung cancer) suggest that, despite its higher cost
compared with zoledronic acid, denosumab is cost-effective for the
health care system when SRE-related costs and administration costsClinical Lung Cancer November 2015 - 433
Table 1 Skeletal-Related Event Efﬁcacy Results in a Phase III Study of Denosumab in Patients With Bone Metastases From Solid
Tumors/MM
Solid Tumor/MM
(n [ 1776)41
Solid Tumor Subset
(n [ 1597)54
NSCLC Subset
(n [ 702)41
Delay in Time to First SRE
During Study
HR ¼ 0.84(95% CI, 0.71-0.98);P ¼ .0007,
noninferiority test; adjusted
P ¼ .06, superiority test
HR ¼ 0.81(95% CI, 0.68-0.96);P ¼ .001,
noninferiority test;
adjusted P ¼ .017, superiority test
HR ¼ 0.85(95% CI, 0.65-1.12);
P ¼ .25
Median Time to First SRE
During Study
20.6 Months for denosumab;
16.3 months for ZA
21.4 Months for denosumab;
15.4 months for ZA
NR
Delay in Time to First and
Subsequent SRE
RR ¼ 0.90(95% CI, 0.77-1.04);
adjusted P ¼ .14
RR ¼ 0.85(95% CI, 0.72-1.00);
adjusted P ¼ .048
RR ¼ 0.89(95% CI, 0.69-1.15);
adjusted P ¼ .38
Abbreviations: CI ¼ conﬁdence interval; HR ¼ hazard ratio; MM ¼ multiple myeloma; NR ¼ not reported; NSCLC ¼ nonesmall-cell lung cancer; RR ¼ rate ratio; SRE ¼ skeletal-related event;
ZA ¼ zoledronic acid.
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434 -(approximately 3 times higher for zoledronic acid) are taken into
account (Table 3).40,44,55-60An independent economic evaluation59
concluded that, with the patient access scheme, denosumab is cost-
effective relative to zoledronic acid but not to best supportive care.
However, because of between-country variation in net drug prices of
the 2 drugs it is not possible to reach a general conclusion about this
question.
Denosumab for the Prevention of
Bone Metastasis
There are currently no data available regarding prevention of
bone metastasis for patients with lung cancer, which is not an
approved indication of denosumab. There is evidence from a phase
III study in prostate cancer, which found a signiﬁcantly prolonged
median bone metastasis-free survival with denosumab versus
placebo (median of 29.5 months vs. 25.2 months, respectively, HR,
0.85 [95% CI, 0.73-0.98], P ¼ .028). Overall survival was
similar.61Table 2 Safety Results for Overall Study Population (Phase III
Study in Patients With Solid Tumors/Multiple
Myeloma)
Event
Denosumab
(n [ 878)
Zoledronic Acid
(n [ 878)
Overall AEs 95.8% 95.9%
Adverse Events That Occurred With ‡25% Frequency in Either Arm
Nausea 28.2% 30.3%
Anemiaa 27.6% 32.6%
Dyspnea 25.1% 22.8%
Fatigue 24.0% 25.1%
Adverse Events of Interest
Hypocalcemia 10.8% 5.8%
Renal AEs 8.3% 10.9%
Acute phase reactions
(within the ﬁrst 3 days)a
6.9% 14.5%
Osteonecrosis of the jaw 1.1% 1.3%
Data not adjusted for multiplicity.
Abbreviation: AEs ¼ adverse events.
aP < .05.
Clinical Lung Cancer November 2015Denosumab for the Prolongation of
Overall Survival
Data that suggest efﬁcacy of denosumab in prolongation of
overall survival in lung cancer patients come from a post hoc sur-
vival analysis of the phase III study in patients with solid tumors and
multiple myeloma.41,62 A post hoc analysis was conducted in a total
of 811 eligible adult patients with lung cancer. Most of these pa-
tients (88% in the zoledronic acid group and 85% in the denosu-
mab group) had NSCLC (adenocarcinoma, squamous cell
carcinoma, or other).62 In patients with lung cancer (all types
combined), denosumab prolonged median overall survival by 1.2
months compared with zoledronic acid. Median overall survival was
8.9 months for patients who received denosumab and 7.7 months
for patients who received zoledronic acid, a 20% reduction in risk
with denosumab (HR, 0.80; 95% CI, 0.67-0.95; P ¼ .01;
Table 462 and Figure 2).62 In the subgroup of patients with
NSCLC, denosumab prolonged median overall survival by 1.5
months compared with zoledronic acid (median 9.5 months vs. 8.0
months, respectively), with a 22% reduction in risk (HR, 0.78;
95% CI, 0.65-0.94; P ¼ .01).62 The reduction was also signiﬁcant
in the subset with squamous cell carcinoma (median 8.6 months vs.
6.4 months; HR, 0.68; 95% CI, 0.47-0.97; P ¼ .035), whereas it
did not achieve statistical signiﬁcance in patients with adenocarci-
noma (median 9.6 months vs. 8.2 months; HR, 0.80; 95% CI,
0.62-1.02; P ¼ .075; Table 4).62 When it was analyzed according to
the presence of visceral metastases, denosumab signiﬁcantly pro-
longed survival in the subset with visceral metastases (median 7.7
months vs. 6.4 months; HR, 0.79; 95% CI, 0.63-0.98; P ¼ .03),
whereas there was only a trend in the subset without visceral me-
tastases (median 10.8 months vs. 9.6 months; HR, 0.81; 95% CI,
0.62-1.06; P ¼ .12).62 The data were not analyzed according to
epidermal growth factor receptor (EGFR) mutations in exons
19/21, EGFR T790M mutation status, or presence of anaplastic
lymphoma kinase (ALK)-echinoderm microtubule-associated
protein-like 4 (EML4) rearrangements.
The retrospective, unplanned nature of lung cancer survival data
implies risk of bias and imposes some caution on their interpreta-
tion. However, several baseline variables, including age and ECOG
status, did not account for the improved overall survival observed in
denosumab-treated patients,62 and further investigations to conﬁrm
these results in prospective studies are ongoing.63,64
Table 3 Denosumab Versus Zoledronic Acid: Drug Characteristics and Cost-Effectiveness Comparisons in Lung Cancer Patients or Solid Tumor Patients (Including Lung Cancer)
Drug
Drug Characteristics
Chemical
Composition
Mechanism
of Action
Administration Route/
Frequency/Dose Unit
Dose Adjustment in Patients
With Renal Dysfunction
Common (‡1/100) Adverse Reactions and/or
Adverse Reactions of Special Interest
Denosumab
(XGEVA)44
Fully human monoclonal
antibody against RANKL
Binding to RANKL,
preventing the RANKL/
RANK interaction from
occurring and resulting in
reduced osteoclast
numbers and function
Subcutaneous
Every 4 weeks
120 mg
No dose adjustment is required in patients
with renal impairment (see recommendations
relating to monitoring of calcium)
No need for renal monitoring
Patients with severe renal impairment
(CrCl <30 mL/min) or receiving dialysis are at
greater risk of developing hypocalcemia. Regular
monitoring of calcium levels is especially
important in these patients
Common:
Hypocalcemia, hypophosphatemia, dyspnea, diarrhea, tooth extraction,
hyperhidrosis, musculoskeletal pain, osteonecrosis of the jaw
Of special interest:
Hypocalcemia (9.6%)
Osteonecrosis of the jaw (1.8%)
Drug-related hypersensitivity reactions (rare)
Atypical fractures of the femur (rare)
Musculoskeletal pain (very common)
Zoledronic Acid
(Zometa)40
Chemical Agent
(bisphosphonate, synthetic
analogue of endogenous
pyrophosphate)
Selective binding to bone
matrix and inhibition of
osteoclast activity after
their internalization in
places of bone resorption
Intravenous (infusion
during at least 15 minutes)
Every 3-4 weeks
4 mg
It cannot be administered in patients
with CrCl <30 mL/min
The initial dose must be adjusted in
patients with CrCl 30-60 mL/min
The renal function must be monitored in all
patients before administration
In patients who show evidence of renal
deterioration, treatment should be withheld
and only be resumed when serum creatinine
returns to within 10% of baseline
Common:
Anemia, headache, conjunctivitis, nausea, vomiting, decreased appetite,
bone pain, myalgia, arthralgia, generalized pain, renal impairment,
fever, ﬂu-like syndrome, hypophosphatemia, blood creatinine and blood
urea increased, hypocalcemia
Of special interest:
Renal function impairment (common, lung tumors: 3.2%)
Osteonecrosis of the jaw (uncommon)
Atrial ﬁbrillation (2.5%)
Acute phase reactions (common)
Atypical fractures of the femur (rare)
Hypocalcemia (5.0%)
Cost-Effectiveness Comparisons
Reference Country Study Design Population Model Inputs and Drug Costs Main Results Conclusions
Bell et al,
201160
US  Excel-based model
 1- to 3-year time horizons
 Hypothetical managed care
plan with 1 million members and
688 patients with solid-tumor
bone metastases
 Costs: drug acquisition and
administration, SRE management,
and AE treatment under
2 scenarios
 Base case ZA-only formulary;
restricted-formulary case: Dmab
limited to second-line treatment
in patients in whom ZA had failed
 Patients with solid tumor
bone metastases
Drug costs:
 Dmab: $1650
 ZA: $878
Model inputs:
Model parameters derived from pub-
lished literature, product labels,
clinical trial data, and
administrative cost databases
 Total costs in base case ZA
scenario: $10.8 million per year
 Total costs in allowing restricted
access to Dmab: $11.3, $11.5,
and $11.7 million over 1, 2,
and 3 years, respectively ($0.05,
$0.06, $0.08 incrementally per
member per month)
 The corresponding incremental
cost of adding Dmab was $68,
$93, and $113, respectively, per
ZA-treated member per month.
Corresponding reductions in
annual SREs were 12, 18, and 22
Restricted use of Dmab adds
considerably to patient
management costs
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Table 3 Continued
Cost-Effectiveness Comparisons
Reference Country Study Design Population Model Inputs and Drug Costs Main Results Conclusions
Lothgren et al,
201155
Netherlands  3 Lifetime Markov cohort models
(per each cancer type)
 Payer perspective
 Costs: treatment, drug
administration, SREs, and AEs
 Cycle length: 4 wks
 Costs discounted at 4%
annually and QALYs discounted
at 1.5% annually
 Patients with bone metastases
from breast cancer, prostate
cancer and other solid tumors
excluding multiple myeloma
Model inputs:
 Constant SRE incidence rates
estimated from the clinical trials
 Trial-based discontinuation
 SRE-related utility decrements
derived from trial-based EQ-5D data.
 SRE-related costs and
administration cost were
based on local data
 Dmab resulted in fewer SREs,
higher QALYs, lower SRE-related
costs, lower administration cost,
and higher medication and total cost
 The predicted ICER per SRE avoided
in patients with other solid tumors
was V690 and the ICER per QALY
gained was V11,660
 Administration costs were important
drivers of results
Dmab is cost-effective versus ZA in
The Netherlands and represents good
value for money in prevention of SREs
in patients with bone metastases from
all advanced solid tumors based on
commonly accepted thresholds
Stopeck et al,
201257
US  Lifetime Markov cohort model
 US managed care perspective
 Costs: treatment, drug
administration, SREs, and AEs
 Cycle length: 4 weeks
 Costs and QALYs were
discounted at 3% annually
 Patients with CRPC, breast
cancer, and NSCLC with
bone metastases
Drug costs:
 Dmab: $1650 (drug) þ $35.42
(administration)
 ZA: $895.61 (drug) þ $154.64
(administration) þ $21.43 (renal
monitoring)
Model inputs:
 SRE rates in ZA-treated patients
were derived from a large
commercial database (PharMetrics
integrated database)
 SRE and treatment administration
QALY decrements were estimated
with time trade-off studies
 SRE costs were estimated from a
large representative US
commercial claims database
 With drug discontinuation, cost per
QALY gained for NSCLC was
reduced to $49,781
 Most inﬂuential variables were drug
costs and SRE rates
 Probabilities of Dmab being
cost-effective versus ZA in NSCLC
patients with ICER thresholds of
$100,000, $150,000, and
$200,000, respectively: 0.60, 0.72,
and 0.78
Dmab is a cost-effective treatment
option for the prevention of SREs in
patients with advanced solid tumors
and bone metastases compared
with ZA
Lothgren et al
201356
Austria, Sweden,
and Switzerland
 Analyses of the cost implications
per patient, per year, and to predict
the potential annual budget effect
when patients are transitioned from
treatment with ZA to Dmab
 1-year time horizon
 Patients with bone
metastases from solid tumors
Drug costs: Austria/Sweden/Switzerland:
 Dmab: V371.00/354.40/452.46
(drug) þ V10.98/46.48/47.94
(administration)
 ZA: V303.10/308.79/336.71
(drug) þ V29.55/151.10/144.79
(administration) þ V7.46/3.08/
2.10 (renal monitoring)
Model inputs:
 Drug administration and patient
management costs were taken
from available public sources.
 SRE costs were based on local
unit costs applied to country-speciﬁc
health care resources obtained
from a multinational retrospective
chart review study
 SRE rates were derived from
phase III clinical trials
 Estimated total annual cost savings
for each patient transitioned from
ZA to Dmab varied by country and
cancer type, ranging from V1583
to V2375 in Austria, from V1980
to V2319 in Sweden (9.1 SEK/V)
and from V3408 to V3857 in
Switzerland (1.2 CHF/V)
 Cost savings were mainly driven
by the lower SRE related costs and
lower administration costs of Dmab
compared with ZA
Cost savings are predicted in the
Austrian, Swedish and Swiss health
care systems following treatment
transition from ZA to Dmab
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Table 3 Continued
Cost-Effectiveness Comparisons
Reference Country Study Design Population Model Inputs and Drug Costs Main Results Conclusions
Durán et al,
201358
Spain  Lifetime Markov cohort model
 Spanish Health System’s perspective
 Costs: treatment, drug
administration, SREs and AEs
 Cycle length: 4 weeks
 Costs and QALYs were
discounted at 3% annually
Drug costs:
 Dmab: V293 (drug) þ V14.58
(administration) þ V7.17 (calcium
monitoring)
 Generic ZA: V153.82 (drug) þ
V135.03 (administration) þ V13.6
(calcium and renal monitoring)
Model inputs:
 Administration and monitoring costs
applied only to doses not
synchronized with intravenous
chemotherapy
 Transition probabilities, AE rates,
and rate of SRE obtained from
clinical trials
 Denosumab was dominant (more
efﬁcacious and less costly) in 69%
of scenarios and remained
cost-effective in 97% (using
V30,000/QALY threshold)
Denosumab is cost-effective versus
generic ZA in the prevention of
SRE in patients with bone metastases
from solid tumors and is cost-saving
in most scenarios
Ford et al
201359
UK  Systematic review of published
and unpublished reports on the
clinical effectiveness and cost-
effectiveness of Dmab
 Independent economic assessment:
costeutility Markov model; 4-week
cycle; lifetime horizon for the
base case
Patients with bone metastases
from CRPC, breast cancer, and
NSCLC or other solid tumors
Annual drug costs:
 Dmab: £4466.80 without a PAS
 ZA: £3364.66 (British National
Formulary 62 states £3245.97);
These costs do not include withheld
doses due to poor renal function,
or any patient management costs
due to poor renal function. Without
the PAS the annual Dmab cost is
approximately £1102 more
expensive than ZA
Model inputs:
 Inputs of the manufacturer’s
model amended using network
meta-analysis. Structural model
elements added: spinal cord
compression having a sustained
effect on quality of life beyond 5
months, and a decay in quality
of life in the ﬁnal year
 In lung cancer, the net gain in
quality of life in patients treated with
Dmab compared to ZA among the
subgroup who had experienced a
prior SRE was 0.003 QALYs, and,
in the SRE-naive subgroup, 0.006
QALYs.
 With the PAS, the additional cost
of £43 results in a cost-
effectiveness of £12,743 per QALY
Dmab is in the main estimated to
dominate or be cost-effective
compared with ZA. Only a relatively
minor price reduction for ZA is
required to result in the additional
net costs from Dmab rendering it
not cost-effective at
current thresholds
Abbreviations: AE ¼ adverse event; CrCl ¼ creatinine clearance; CRPC ¼ castration-resistant prostate cancer; Dmab ¼ denosumab; EQ-5D ¼ European Quality of Life-5 Dimensions questionnaire; ICER ¼ incremental cost-effectiveness ratio; NSCLC ¼ nonesmall-cell lung
cancer; PAS ¼ patient access scheme; RANK ¼ receptor activator of nuclear factor-kB; RANKL ¼ RANK ligand; QALY ¼ quality-adjusted life-year; SRE ¼ skeletal related event; ZA ¼ zoledronic acid.
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Table 4 Overall Survival Results in a Post Hoc Analysis of a Phase III Study62
Median OS
HR (95% CI; P Value)Denosumab Arm ZA Arm
Lung Cancer Subset (Any Type; n [ 811) 8.9 Months 7.7 Months 0.80 (0.67-0.95; .01)
NSCLC Subset (n [ 702) 9.5 Months 8.0 Months 0.78 (0.65-0.94; .01)
Adenocarcinoma (n [ 400) 9.6 Months 8.2 Months 0.80 (0.62-1.02; .075)
SCC (n [ 163) 8.6 Months 6.4 Months 0.68 (0.47-0.97; .035)
SCLC Subset (n [ 109) 7.6 Months 5.1 Months 0.81 (0.52-1.26; .36)
Abbreviations: HR ¼ hazard ratio; NSCLC ¼ nonesmall-cell lung cancer; OS ¼ overall survival; SCC ¼ squamous cell carcinoma; SCLC ¼ small-cell lung cancer; ZA ¼ zoledronic acid.
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438 -Ongoing Studies of Denosumab in
Lung Cancer
The European Thoracic Platform is conducting an open-label,
phase III, prospective trial (SPLENDOUR; Survival imProvement
in Lung cancEr iNduced by DenOsUmab theRapy63) on the
potential of denosumab as an antitumor agent to increase survival
of patients in collaboration with the European Organization for
Research and Treatment of Cancer. In this study, 1000 patients
with untreated advanced NSCLC, with or without bone metas-
tases (stratiﬁcation factor), will be randomized to 4 to 6 cycles of
doublet platinum-based chemotherapy with denosumab 120 mg
subcutaneously (SC) every 4 weeks or chemotherapy with best
supportive care. The primary end point is overall survival, and
secondary end points are progression-free survival, tumor
response, toxicity, and tumor tissue and blood biomarkers for
efﬁcacy of denosumab, such as C-terminal telopeptide of type 1
collagen (CTX), N-terminal telopeptide of type I collagen (NTX),
OPG, propeptide of type I procollagen, bone sialoprotein,
osteopontin, free RANKL, and RANKL-OPG. Recruitment will
last approximately 3 years, until the required number of 847Figure 2 Post Hoc Analysis of a Phase III Study in Patients
With Bone Metastases (Lung Cancer Subgroup):
Overall Survival Was Improved in Patients Who
Received Denosumab Versus Those Who Received
Zoledronic Acid
Reprinted by permission from Wolters Kluwer publishers: Scagliotti et al. Overall survival
improvement in patients with lung cancer and bone metastases treated with denosumab versus
zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012;
7:1823-1829.
Clinical Lung Cancer November 2015events is observed at the estimated maximum trial duration of 51
months. The trial has been designed with an interim analysis to
test for futility at 30% of the overall study information time,
when 254 deaths have been observed. If the futility boundary is
crossed, the trial might be closed on the basis of the recom-
mendation of the Independent Data Monitoring Committee. If
the futility boundary is not crossed, the study will continue to
completion as planned.
The second ongoing study, which has already completed
recruitment, is a double-blind, randomized phase II trial on the
effect of the combination of denosumab with standard ﬁrst-line
chemotherapy in the treatment of metastatic NSCLC
(ClinicalTrials.gov Identiﬁer: NCT01951586).64 In this study, 216
patients with untreated advanced NSCLC with or without bone
metastases will be randomized in a 2:1 fashion to receive denosumab
120 mg or placebo SC every 3 or 4 weeks with a loading dose on
day 8. In both arms, patients will also receive 4 to 6 cycles of
standard of care platinum-doublet chemotherapy. The primary end
point is overall survival according to tumor tissue RANK expression,
and secondary end points include safety and response according to
tumor tissue RANKL expression or according to other potential
blood, urine, and/or tumor tissue biomarkers.
Potential Antitumor Effects of
Denosumab
Biological Mechanisms
Several hypotheses have been postulated to explain the beneﬁt in
overall survival observed with denosumab in lung cancer patients.
They include direct and indirect antitumor effects of antiresorptive
drugs. Direct effects on tumorigenesis are increasingly being re-
ported in the literature, and might result from direct drugetumor
cell interaction (ie, ligand receptor). The cells that express the re-
ceptor could be either a primary tumor or metastatic cells. Other
effects might result from indirect mechanisms, for example, sec-
ondary to changes in the microenvironment or a drugenontumor
cell interaction (Figure 3).48
Direct DrugeTumor Cell Interaction
Evidence of RANKL Expression by Tumor Cells. Receptor activator
of nuclear factor-kB expression and RANK/RANKL signaling are
not limited to the bone.65,66 RANKL is expressed on a number of
different tumor types including prostate cancer,67-69 breast can-
cer,70,71 multiple myeloma,72-74 renal carcinoma,75 and lung cancer
cells.62 It has been observed that this expression is modulated by
Figure 3 Potential Direct and Antidirect Effects of Antiresorptive Drugs on Tumorigenesis
Adapted by permission from Macmillan Publishers Ltd: Nat Rev Cancer, 2002;2:584-593; copyright 2002.
Javier De Castro et alseveral cytokines and hormones, such as transforming growth factor
B (TGF-B), interleukin 1, 6, 4, and 18, parathyroid hormone, 1,25
dihydroxyvitamin D3, calcitonin, prostaglandins, and
corticosteroids.47
Receptor activator of nuclear factor-kB and RANKL have been
found to be expressed in the tumor epithelium of primary human
NSCLC samples, which supports the hypothesis for a potential
direct antitumor effect of denosumab in lung cancer. Among 16
tissue samples with adenocarcinoma histotype, 56% expressed
RANK, 75% expressed RANKL, and 37% expressed both. Among
26 tissue samples with squamous-cell carcinoma histotype, 34%
expressed RANK, 19% expressed RANKL, and 8% expressed
both.76
The mechanisms that explain upregulation of RANKL
expression in cancer are unknown, but it seems to result in
subsequent paracrine or autocrine activity, for example, an in-
crease in the expression of genes involved in osteolysis, migration,
and invasion. This has been demonstrated in prostate and breast
cancer cells.67,77-81 Results of some in vitro studies have suggested
direct effects of denosumab on tumorigenesis in mammary
epithelial cells,66 modulation of the progesterone/RANKL
axis,65,66,82,83 and immunomodulatory effects.84-87 All of these
RANKL-mediated mechanisms must be further clariﬁed and
investigated.Changes in Biochemical Signaling
Promotion of Tumor Cell Apoptosis. Blocking the RANK/RANKL
pathway with denosumab could result in inhibition of nuclear
factor (NF)-kB signaling.46,47,88 RANK and RANKL are members
of the TNF/TNF receptor superfamily.45 RANK stimulation
activates different signaling pathways, including the canonical
and alternative NF-kB pathways, to control osteoclastogenesis
(Figure 4).88 RANK-mediated NF-kB activation is dependent on a
complex formation between p62 and TNF receptor-associated
factor 6 (TRAF6).89 TRAF6- and p62-mediated NF-kB activation
in lung cells by RANKL is under investigation.90
Nuclear factor kB is involved in multiple steps in carcinogenesis
and in the resistance of cancer cells to chemotherapy and radio-
therapy.91 Studies in animal models and cell culture systems have
established links between NF-kB and lung carcinogenesis.91 Acti-
vation of NF-kB signaling confers resistance to apoptosis in EGFR-
mutant lung adenocarcinoma cell lines.92 NF-kB in lung tumor
cells also induces the expression of tissue inhibitor of metal-
loproteinase 1, an important regulator of extracellular signal-
regulated kinase (ERK) activity and cell proliferation.93
Decrease Migration of Tumor Cells. In preclinical studies, deno-
sumab has been shown to inhibit RANK-expressing tumor cell
migration.44,94,95 In lung cancer cells, RANKL increasesClinical Lung Cancer November 2015 - 439
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440 -intercellular adhesion molecule 1 expression, which enhances the
migration of cells. RANKL stimulation also increases MEK/ERK
phosphorylation, which suggests that migration of lung cancer cells
could be modulated by the RANK-mitogen-activated protein kinase
signal transduction cascade (Figure 5).95 In prostate cancer cells,
RANKL inhibition blocked migration of RANK-expressing prostate
cancer cells.94
Indirect Antitumor Mechanisms
Less “Fertile” Bone Microenvironment. Tumor-derived factors
stimulate increased bone resorption by osteoclasts, which in turn
release bone-derived growth factors (including TGF-B and insulin-
like growth factor) and calcium from the bone matrix into the
bone microenvironment.48 In turn, this stimulates further tumor
cell proliferation and further production of tumor-derived factors
that stimulate osteoclast-mediated bone destruction.46,48,96 Indi-
rect effects of bone-targeted drugs on tumorigenesis might result
from blocking the vicious cycle secondary to inhibition of
osteoclast-mediated bone resorption. In this way, antiresorptiveFigure 4 Links Between the RANK/RANKL Pathway and Nuclear Fac
Extracellular Stimuli That Activate NF-kB
Abbreviations: OPG ¼ osteoprotegerin; TIMP ¼ tissue inhibitor of metalloproteinase.
Reprinted by permission from John Wiley & Sons, Inc. Publishers: Leibbrandt A, Penninger JM
2008;1143:123-150.
Clinical Lung Cancer November 2015drugs could have an indirect effect on the bone microenvironment
that make the bone less hospitable for tumor growth.
Decrease Invasion by Tumor Cells. In mouse bone metastasis
models of estrogen receptor-positive and -negative human breast
cancer, prostate cancer and NSCLC, OPG-fragment crystalline
(Fc) (a RANKL inhibitor used in mouse models) reduced osteo-
lytic, osteoblastic, and osteolytic/osteoblastic lesions, delayed for-
mation of de novo bone metastases, and reduced skeletal tumor
growth.44 When OPG-Fc was combined with hormonal therapy
(tamoxifen) or chemotherapy (docetaxel) in these models, there
was an additive inhibition of skeletal tumor growth in breast,
prostate, or lung cancer, respectively.44 The selective estrogen re-
ceptor modulation induced by tamoxifen might explain this syn-
ergistic effect because endogenous OPG expression is induced by
factors that block bone catabolism and promote anabolic effects,
like estrogens (Figure 6). In immunodeﬁcient mice, the NSCLC
cell line A549 formed a mixed osteolytic/osteoblastic lesion
in vivo. Treatment of these mice with RANK-Fc limited thetor (NF)-kB: RANK Is One of Numerous Intracellular and
. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci.
Figure 5 Proteins With Validated Effects Involved in RANK Signal Transduction During Osteoclast Development and Activation. Red
Bars Indicate Target of Known Small-Molecule Inhibitors
Reprinted by permission from Macmillan Publishers Ltd: Nature 2003;423:337-342, copyright 2003.
Javier De Castro et alformation of the lytic aspect of the mixed lesion and also inhibited
tumor growth.97
Discussion
The important burden and effect on quality of life of bone me-
tastases and SREs in lung cancer patients requires an effective
therapeutic management. Bone-targeted agents delay complications,
relieve symptoms, and improve quality of life, and should be
commenced at the time of diagnosis of metastatic bone disease.
They might also help delay the decrease in ECOG performance
status associated with SREs.22-24
Current National Comprehensive Cancer Network (NCCN)
and European Society of Medical Oncology (ESMO) guidelines
for treatment of bone metastases in NSCLC, and ESMO rec-
ommendations on bone health in cancer patients recommend
either denosumab or zoledronic acid in patients with proven
bone metastasis (Table 5).9,15,28,34,35,98-100 In addition, the
ESMO NSCLC guideline15 states that denosumab shows a
trend toward superiority to zoledronic acid in terms of SRE
prevention and the NCCN NSCLC guideline34 recognizes that
current data suggest superiority of denosumab in increasing
overall survival. The link between these ﬁndings and the pre-
clinical evidence that shows that denosumab might inhibit
tumorigenesis remains unknown. Besides efﬁcacy considerations,
denosumab does not undergo renal elimination101 and some
studies have demonstrated that the safety and efﬁcacy of deno-
sumab are not affected by renal insufﬁciency, except for a greaterrisk of hypocalcemia with renal dysfunction.44,102 Thus, this
bone-targeted agent might be more suitable than zoledronic acid
in lung cancer patients.
Regarding the prevention of SREs, further studies would be of
interest to establish the optimal timing and duration of denosu-
mab therapy and the utility of bone resorption markers (such as
NTX) for the selection of candidate patients and for evaluation of
treatment response. The recent ESMO guidelines for maintaining
bone health in patients with cancer9 recommend giving bone-
targeted agents indeﬁnitely. The Central European Cooperative
Oncology Group (CECOG) guideline on denosumab use98 rec-
ommends initiation at diagnosis of bone metastasis in all patients
with ECOG performance status of 0 to 3 and a life expectancy > 3
months, and continuation at least until the occurrence of unac-
ceptable toxicity.
Regarding prevention of bone metastasis and antitumor activity,
denosumab has shown clinical and preclinical evidence of anti-
resorptive activity (inhibition of osteoclast formation, function, and
survival) and inhibition of the ‘vicious cycle’ through modulation of
the bone microenvironment. The possible modulation of these ef-
fects by genetic tumor biomarkers (such as EGFR or Ki-ras2 Kirsten
rat sarcoma viral oncogene homolog (KRAS) mutations or EML4-
ALK rearrangements) is unknown. The 2 ongoing clinical trials in
lung cancer (SPLENDOUR63 and NCT0195158664), which
include response according to several tumor tissue and blood bio-
markers as secondary end points, might help to clarify these issues.
In addition, more basic scientiﬁc research is needed to clarify theClinical Lung Cancer November 2015 - 441
Figure 6 Possible Synergistic Effect Between Denosumab and Tamoxifen. (A) RANKL Expression Is Induced by Proresorptive and
Calcitropic Factors, Which Promote Osteoclast Differentiation, Activation, and Survival; (B) OPG Expression Is Induced by
Factors That Block Bone Catabolism and Promote Anabolic Effects, Like Estrogens, Which Neutralizes RANKL, Leading to a
Block In Osteoclastogenesis and Decreased Survival of Pre-Existing Osteoclasts
Reprinted by permission from Macmillan Publishers Ltd: Nature 2003;423:337-342, copyright 2003.
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Table 5 Current Guideline Recommendations on the Use of Denosumab in Lung Cancer
Institution Guideline Recommendations Regarding Treatment and/or Prevention of Skeletal Complications
NCCN 2015-2016 NSCLC (v7.2015)34 Treatment of distant metastases: bisphosphonate therapy or denosumab can be considered in patients with
bone metastasis. In patients with NSCLC who have bone metastases, data suggest that denosumab increases
median overall survival compared with zoledronic acid (9.5 vs. 8 months). Denosumab can be associated with
severe hypocalcemia; patients with hypoparathyroidism and vitamin D deﬁciency are at increased risk for
hypocalcemia. The US Food and Drug Administration has approved the use of zoledronic acid and denosumab
in patients with bone metastases from solid tumors
SCLC (v1.2016)35 No mention of denosumab or other bone-targeted agents
ESMO 2013-2014 NSCLC (2014)15 Bone metastasis-modifying agents:
 Zoledronic acid reduces SRE and is recommended in stage IV bone metastatic disease [II; B].
 Denosumab is not inferior [I;A], and shows a trend toward superiority, to zoledronic acid in lung cancer in terms
of SRE prevention [II;B]
SCLC (2013)99 No mention of denosumab or other bone-targeted agents
ESMO 2014 Bone health in cancer
patients9
Bone metastases:
 The bisphosphonates and denosumab are inhibitors of osteoclast activity that have become important agents
for the treatment of metastatic bone disease, because they delay complications, relieve symptoms and improve
quality of life (I, A)
 Zoledronic acid is the most effective bisphosphonate for prevention of morbidity from metastatic bone disease (I, B)
 Denosumab is more effective than zoledronic acid for prevention of skeletal morbidity from solid tumors (I, B)
 Bone-targeted therapy should be commenced at diagnosis of metastatic bone disease (III)
 Bone-targeted therapy for metastatic bone disease should continue indeﬁnitely and throughout the
course of the disease (III)
CECOG 2013 Denosumab in the
prevention of SREs in
bone metastases from
lung cancer98
Recommendations on denosumab use:
 Indication: denosumab is indicated for the prevention of SREs in patients with bone metastases from solid tumors.
All patients who suffer from advanced lung cancer with proven skeletal metastases should be considered
candidates for denosumab. Denosumab should be used in patients with Eastern Cooperative Oncology Group
performance status of 0-3 and a life expectancy >3 months
 Timing and duration: denosumab should be started at diagnosis of bone metastases and treatment should
not be delayed. Treatment should be continued at least until the occurrence of unacceptable toxicity
 Prophylactic use in patients without bone metastases: at present, not recommended
 Use in patients with mutations (EGFRm, EML4 ALK): data are not available; however, an interaction
with speciﬁc targeted therapies has no biological rationale (data on toxicity are needed)
Use in SCLC: There is inconclusive evidence regarding survival beneﬁts for patients with SCLC. In these patients,
besides chemotherapy, bone-modifying agents are also recommended in the presence of bone metastases to
prevent SREs
Safety recommendations:
 Hypocalcemia: prophylactic use of calcium and vitamin D is indicated, if calcium levels are not at increased
levels. Hypocalcemia must be corrected before treatment with denosumab. Calcium levels should be checked
every 3 months
 ONJ: standard examination of dental status (anamneses, inspection) should be conducted. If a disease-suspected
focus or a history is found, further examinations are indicated (dentist). Start of denosumab treatment should be
delayed, until potential focus is excluded or treated (see AAOMS guidelines).28 Otherwise, beneﬁt:risk ratio is well
balanced. Focus should be laid on patient education and oral hygiene. Dental interventions should be avoided
whenever possible
 Use in combination with bisphosphonates: not recommended
SEOM 2012 Bone metastases
from solid tumors103
Algorithm for treatment with bone-modifying agents in patients with bone metastases conﬁrmed using
imaging methods:
 Normal renal function (crCL >60 mL/min): denosumab SC 120 mg for 4 weeks or
zoledronic acid I.V. 4 mg for 3-4 weeksa
 Altered renal function (crCL <60 and >30 mL/min): denosumab SC 120 mg for 4 weeks or
zoledronic acid I.V. 3.5-3.0 mg for 3-4 weeksa
 Altered renal function (crCL <30 mL/min): denosumab SC 120 mg for 4 weeks
Abbreviations: AAOMS ¼ American Association of Oral and Maxillofacial Surgeons; ALK ¼ anaplastic lymphoma kinase; CECOG ¼ Central European Cooperative Oncology Group; crCL ¼ creatinine
clearance; EGFRm ¼ epidermal growth factor receptor mutant; EML4 ¼ echinoderm microtubule-associated protein-like 4; ESMO ¼ European Society of Medical Oncology; NCCN ¼ National
Comprehensive Cancer Network; NSCLC ¼ nonesmall-cell lung cancer; ONJ ¼ osteonecrosis of the jaw; SC ¼ subcutaneously; SCLC ¼ small-cell lung cancer; SEOM ¼ Sociedad Española de
Oncología Médica; SRE ¼ skeletal-related events.
aIn case of intense acute phase reaction to zoledronic acid or deterioration of renal function: denosumab SC 120 mg for 4 weeks.
Javier De Castro et alpotential of denosumab to affect the bone microenvironment and
reduce tumor aggressiveness and metastatic capabilities.
Other pending questions are the potential synergistic action of
denosumab with novel biologic agents, such as crizotinib or other
ALK inhibitors, erlotinib, geﬁtinib, afatinib, and bevacizumab.
The CECOG guideline98 states that concomitant use of denosu-
mab with targeted therapies is not discarded, although the grouprecognizes that no data are available. There is a case report of a
patient with metastatic adenocarcinoma of the lung who harbored
an ALK gene translocation and whose tumor responded to treat-
ment with denosumab, which suggests a possible link between
ALK and RANK.103 Because of the extreme heterogeneity of lung
cancers, treatment individualization might be crucial to improve
outcomes with the new biological therapies. The consistentClinical Lung Cancer November 2015 - 443
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444 -antitumor effect of denosumab in all of these subpopulations is
pending investigation.
Conclusion
Bone metastases are common in lung cancer and should
be treated with a bone-targeted agents before debilitating compli-
cations, including pain and skeletal complications occur. Denosu-
mab has been shown to reduce the risk of SREs in patients with
bone metastasis from solid tumors, in patients with and without
previous SREs. Denosumab was shown to be superior to zoledronic
acid in a post hoc survival analysis of lung cancer patients in a phase
III SRE prevention trial, with improved overall survival compared
with zoledronic acid. A couple of trials are ongoing to prospectively
evaluate the effect of denosumab on overall survival and its use as
ﬁrst-line therapy (in combination with chemotherapy) in patients
with lung cancer. Preclinical studies have established links between
NF-kB signaling and lung carcinogenesis, and RANK and RANKL
are expressed in primary human NSCLC samples, which provides
the rationale for further investigation of the therapeutic potential of
RANKL inhibition in lung cancer.Acknowledgments
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